Thymosin α 1 potentiates interleukin 2-induced cytotoxic activity in mice

Cellular Immunology

Volumn 133, Issue 1, 1991, Pages 196-205

  Mastino, Antonio ^a   Favalli, Cartesio ^a   Grelli, Sandro ^a   Innocenti, Fabrizia ^a   Garaci, Enrico ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; INTERLEUKIN 2; THYMOSIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CYTOTOXICITY; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL;

ANIMAL; CYCLOPHOSPHAMIDE; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; IMMUNITY, CELLULAR; INTERLEUKIN-2; LYMPHOCYTES; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; SPLEEN; SUPPORT, NON-U.S. GOV'T; THYMOSIN;

ANIMALIA;

EID: 0026092975     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/0008-8749(91)90191-D     Document Type: Article

References (35)

1. Analysis of effector mechanisms in cancer
2. Tumour inhibition by interleukin-2 at the tumour/host interface.
3. IN VIVO ADMINISTRATION OF INTERLEUKIN-2 ENHANCES SPECIFIC ALLOIMMUNE RESPONSES
4. Acquired immunological tolerance of foreign cells is impaired by recombinant interleukin 2 or vitamin A acetate.
5. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells
6. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.
7. Synergistic effect of thymosin α1 and αβ-interferon on NK activity in tumor-bearing mice
8. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice.